arrow pharmaceuticals

Arrow Pharmaceuticals Limited

2003 Half Year Results

Friday 22nd August, 2003

arrow pharmaceuticals

Arrow Pharmaceuticals Limited specialises in the sales, marketing and distribution of private and generic prescription drugs in Australia.

arrow pharmaceuticals

Financial Highlights

	Half Year June 2002 ($ m)*	Half Year June 2003 ($ m)	% Increase in 2003
Revenue	112.5	112.0	-
EBITDA	5.8	7.9	36.9%
Profit from Ordinary Activities before Income Tax	5.4	7.4	35.4%
Profit from Ordinary Activities after Income Tax	3.8	5.1	34.8%

* The 2002 Half Year figures are not reviewed accounts, but were incorporated in the financials in the Prospectus dated 30th September 2002

arrow pharmaceuticals

Financial Highlights

	Half Year June 2002 (%)*	Half Year June 2003 (%)
EBITDA/Revenue	5.1%	7.0%
PBT/Revenue	4.8%	6.6%
PAT/Revenue	3.4%	4.6%

* The 2002 Half Year figures are not reviewed accounts, but were incorporated in the financials in the Prospectus dated 30th September 2002

arrow pharmaceuticals

Operational Highlights: 2003

- Cemented position in Private Market
- Increased focus on sales of generic range
- 8 Arrow developed generics now being marketed
- Successful cost containment
- Sales Team strength
- Two contracts for medical team extended for 2003
- Simvastatin license from MSD for November 2004.

arrow pharmaceuticals

EBITDA 2000-2003



Note: During 2000 the Company changed its financial year from a financial year end of 30 June to 31st December. The figure above is obtained from extracting the calendar year EBITDA from the two audited accounts.

Market Outlook

- Continued growth in the Private Prescription market
  - New product introductions
  - PBS budgetary constraints
- Strong generic growth
  - Driven by Patent expiries 2004+
  - Government education initiatives
  - PBS budgetary constraints

arrow pharmaceuticals

The Future

- Opportunity:
  - Major patent expiries 2004-2010

- Objective
  - To capture market share at profitable margins

arrow pharmaceuticals

The Future

- Strategy
  - First-to-Market
  - Integrated pharmacy partnerships
  - Dedicated salesforce
  - Leverage other business segments